King Faisal Specialist Hospital & Research Centre Successfully Concludes its Role as a Strategic Healthcare Partner at Global Health Exhibition 2023

Post Press Release _01

Post Press Release _01

RIYADH, Saudi Arabia, Nov. 06, 2023 (GLOBE NEWSWIRE) — The Global Health Exhibition, held from October 29 to October 31, 2023, proved an outstanding success for the King Faisal Specialist Hospital & Research Centre (KFSH&RC).

As a Strategic Healthcare Partner, KFSH&RC showcased groundbreaking initiatives aimed at enhancing operational efficiency across crucial medical domains, encompassing the patient care journey, space research, genetic studies, state-of-the-art radiation therapy techniques, organ transplantation advancements (including a world-first fully robotic living donor transplant), capacity management, and the production of radiopharmaceuticals to attain self-sufficiency within the Kingdom.

On the inaugural day, H.E Dr. Majid Al Fayyadh delivered a keynote address focusing on the promising future of Medical Tourism in the Kingdom, underscoring KFSH&RC’s continuous efforts to enhance services for international patients. “KFSH&RC’s transformative journey into a non-profit institution, primarily focusing on serving patients from the Gulf region, began in 2021. In its inaugural year, the hospital admitted 250 patients, and we’ve since witnessed an impressive 40% annual growth. We aim to extend our care to 10,000 patients by 2030.”

Dr. Yaseen Mallawi, Acting Chief Executive Officer – Healthcare Delivery at KFSH&RC, participated in a panel discussion addressing “Challenges to accelerating the transformation of the Saudi Health Sector,” where he emphasized the hospital’s commitment to prioritizing patients’ functional well-being within a value-based healthcare system.

Post Press Release _02

Post Press Release _02

Muhannad Al Kadi, Chief Corporate Communications & Marketing Officer at KFSH&RC, expressed his delight at the forum’s success, stating, “It was a pleasure to convene with sector leaders, share our vision, and witness the impact of our collaborations. The Global Health Exhibition has been a remarkable platform to explore new opportunities that will further bolster the healthcare landscape in the Kingdom and beyond.”

KFSH&RC’s experts actively engaged in various panel discussions. Dr. Dieter Broering, Executive Director of the Organ Transplant Center of Excellence, shared insights into the potential of cutting-edge surgical technologies to reshape healthcare. Dr. Mohammed Alhamid, Director of the Centre of Healthcare Intelligence, delivered a thought-provoking speech on AI-powered healthcare, shedding light on the future of healthcare intelligence.

Post Press Release _03

Post Press Release _03

Furthermore, the event marked a significant milestone for KFSH&RC as they celebrated their 100th Car-T Cell procedure, a noteworthy achievement in the Middle East. The hospital also received the prestigious “Best Public Services Call Centre of The Year – Critical” award at the Annual Middle East Call Centre 2023 Awards.

On the sidelines of the Global Health Exhibition, KFSH&RC sealed pivotal MoUs. It partnered with SABIC, a global leader in diversified chemicals, to drive healthcare product development and innovation. King Faisal Specialist Hospital International Holding Company, the investment arm for KFSH&RC, established a strategic partnership with Solutions by STC to enhance the healthcare business landscape and identify mutual growth areas in the sector.

Post Press Release _04

Post Press Release _04

Additional MoUs were signed with Microsoft Arabia, focusing on sustainability and innovation for enhanced patient care, and with the Hevolution Foundation, emphasizing the advancement of longevity and ageing research. KFSH&RC also partnered with Illumina and signed an MoU with Johnson & Johnson, with the primary vision of revolutionizing surgical training in the region.

Contact information:

Photos accompanying this announcement are available at

GlobeNewswire Distribution ID 8973282

Vectara Unveils Open-Source Hallucination Evaluation Model To Detect and Quantify Hallucinations in Top Large Language Models

Groundbreaking Model and Leaderboard Provide New Transparency into Risks Associated with GenAI Chatbots from OpenAI, Anthropic, and Others, Enabling Safer Enterprise Adoption and Objective Government Oversight

SANTA CLARA, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) — Large Language Model (LLM) builder Vectara, the trusted Generative AI (GenAI) platform, released its open-source Hallucination Evaluation Model. This is a first-of-its-kind initiative to proffer a commercially available and open-source model that addresses the accuracy and level of hallucination in LLMs, paired with a publicly available and regularly updated leaderboard, while inviting other model builders like OpenAI, Cohere, Google, and Anthropic to participate in defining an open and free industry-standard in support of self-governance and responsible AI.

By launching its Hallucination Evaluation Model, Vectara is increasing transparency and objectively quantifying hallucination risks in leading GenAI tools, a critical step toward removing barriers to enterprise adoption, stemming dangers like misinformation, and enacting effective regulation. The model is designed to quantify how much an LLM strays from facts while synthesizing a summary related to previously provided reference materials.

“In order to realize the true promise of Generative AI, we first have to tackle the challenge of hallucinations,” said Matei Zaharia, CTO and Co-Founder of Databricks. “The launch of the Hallucination Evaluation Model to the Hugging Face community encourages industry co-innovation and accountability through a powerful measurement tool accessible for all LLM builders.”

The Hallucination Evaluation Model launch includes releasing Vectara’s measurement code base as an open-source model on Hugging Face as well as a publicly accessible Leaderboard available from Vectara. The Leaderboard serves as a quality metric for LLM factual accuracy, similar to how credit ratings or FICO scores function for financial risk, giving businesses and developers insight into the realities of different GenAI tools before implementing them.

“For organizations to effectively implement Generative AI solutions including chatbots, they need a clear view of the risks and potential downsides,” said Simon Hughes, AI researcher and ML engineer at Vectara. “For the first time, Vectara’s Hallucination Evaluation Model allows anyone to measure hallucinations produced by different LLMs. As a part of Vectara’s commitment to industry transparency, we’re releasing this model as open source, with a publicly accessible Leaderboard, so that anyone can contribute to this important conversation.”

Key Features of Vectara’s Hallucination Evaluation Model:

Objective Measurement: This model provides much-needed visibility into the LLMs’ ability to synthesize data without introducing hallucinations. Many LLM vendors make claims about their capabilities to mitigate the impact of hallucinations, but until now, there have been no objectively verifiable methods for detecting and quantifying instances of irrelevant or incorrect data in model outputs. For the model, Vecatara built a machine-learning model, tuned for real world performance and using the latest advancements in hallucination research, to evaluate LLM summarizations without requiring objective scoring or influence.

Transparency Through Open Source: The Hallucination Evaluation Model is available for developers and industry stakeholders to integrate into their own pipelines through an Apache 2.0 License on Hugging Face. Developers can also use the open-source evaluation model to verify the accuracy of Vectara’s platform.

Dynamic Leaderboard: Vectara’s AI researchers and ML engineers (in collaboration with the open source community) will maintain and continually update the Leaderboard, showcasing the hallucination impact of different LLMs and offering a clear comparative perspective as new models emerge. The Leaderboard lists the accuracy and hallucination rates for each model tested in response to the same set of prompts.

The Leaderboard shows that OpenAI’s models have the strongest performance, followed by the Llama 2 models, Cohere and Anthropic. Google’s Palm models scored lower on the Leaderboard.

“Hallucination is one of the most serious issues to consider when deploying production LLMs. Having an open source benchmark model that can evaluate factual accuracy in a quantifiable way will allow developers to directly address the problems,” said Waleed Kadous, Chief Scientist at Anyscale. “Vectara’s new model sets the industry standard for measuring the extent to which LLMs hallucinate, and we’re excited to work with them as a launch partner.”

Vectara has led industry efforts to address hallucinations as a critical barrier to the safe, effective, and accurate use of GenAI. The model doesn’t solve hallucinations directly but rather enables more informed adoption and better decision-making by measuring the frequency and severity of this phenomena. Greater transparency into the quality of LLM-produced summarizations allows LLM users to evaluate GenAI solutions according to the risk profile of the intended use case.

GenAI adoption in highly regulated industries like legal, healthcare, finance, energy, and government will hinge upon vendors’ ability to provide solutions with low to nearly zero risk of factual inaccuracies. Hallucinations have already been raised by stakeholders in these sectors as a serious issue. Until now, however, there has been no way to objectively compare the performance of available models outside of academic benchmarks, which don’t always translate to real-world settings.

Hallucinations also factor heavily in ongoing dialogue about GenAI regulation. Effective government oversight requires measurement tools universally recognized as transparent and objective. Vectara’s open-source model serves as an industry standard, providing the missing link to legislation that virtually all industry leaders agree is needed. With concerns around misinformation and other AI risks rising ahead of the U.S. presidential election and other geopolitical events, the Hallucination Evaluation Model and Leaderboard provide a tangible step toward data-driven and accessible oversight mechanisms.

About Vectara
Vectara is an end-to-end platform that empowers product builders to embed powerful Generative AI features into their applications with extraordinary results. Built on a solid hybrid-search core, Vectara delivers the shortest path to an answer or action through a safe, secure, and trusted entry point. Vectara is built for product managers and developers with an easily leveraged API that gives full access to the platform’s powerful features. Vectara’s Retrieval Augmented (Grounded) Generation allows businesses to quickly, safely, and affordably integrate best-in-class conversational AI and question-answering into their application with zero-shot precision. Vectara never trains their models on customer data, allowing businesses to embed generative AI capabilities without the risk of data or privacy violations. To learn more about Vectara, visit

Media Contact
Carly Bourne

GlobeNewswire Distribution ID 8972422

Henley & Partners and Insignia Join Forces to Create Unique Membership Offering for Global Citizens

LONDON, Nov. 06, 2023 (GLOBE NEWSWIRE) — Henley & Partners, the ‘firm of global citizens’ and leader in residence and citizenship advisory, has partnered with the leading ultra-luxury lifestyle management and card services group, Insignia, to create a distinctive and exclusive membership offering. Henley Global Citizens is a bespoke ‘by invitation only’ service designed to meet the specific needs of wealthy transnational families, entrepreneurs, and investors who do business, invest, and live internationally and who identify themselves as citizens of the world.

Besides priority access, personal introductions, and complimentary consultations with trusted international banks, leading private client lawyers and other top industry professionals in all key jurisdictions worldwide, the Henley Global Citizens offering includes a membership card, which is also a Visa payment card for large, unlimited payments and cash withdrawals, and to make international wire transfers in major currencies. More importantly, it provides access to a dynamic global network of wealthy and influential individuals and families, and an annual calendar of high-level closed-door events, including private dinners at the WEF in Davos, around the UNGA in New York, the Grand Prix in Monaco, and other major business, geopolitical, sporting, and cultural events around the world.

Members and their families can also benefit from complimentary consultation on global education planning and introductions to the world’s top schools and universities, as well as strategic health advice, access to preventive medicine and longevity programs, and the scheduling of medical checkups at the most advanced healthcare locations including Switzerland, Germany, Singapore, the UAE, the UK, and the USA.

Dr. Christian H. Kaelin, Group Chairman of Henley & Partners, says bringing together the high-profile clients of both businesses and combining their expertise to create a unique and exceptional international advisory and service offering is a logical extension for ‘the firm of global citizens’. “For those of us who see ourselves as global citizens, we are not foregoing our other identities, commitment and affiliations to our own countries, culture, religious and even political beliefs. These continue to give us meaning and add value to our lives. But because we are living in an intimately connected and interdependent world, and operating in a global market, we have added another layer of global identity, interest and responsibility. The Henley Global Citizens membership acknowledges and supports this identity and lifestyle in a very practical, everyday way that can add tremendous value for its members.”

Nada T. Rouviere, President of Insignia Group, stated, “Our partnership with Henley & Partners represents a new era in luxury lifestyle management. At Insignia, we have always been dedicated to providing our members with unparalleled experiences, and the Henley Global Citizens card is the embodiment of this commitment. Together with Henley & Partners we are redefining the meaning of global citizenship, offering an exclusive gateway to a world of limitless possibilities and connections. We look forward to enriching the lives of our members by facilitating their journey as true global citizens.”

Henley Global Citizens will be launched at a bespoke event on Friday, 10 November, following the 17th annual Global Citizenship Conference which takes place this week (8-10 November) at the Shangri-La Hotel DIFC in Dubai, UAE.

The international conference hosted by Henley & Partners, where this year over 400 delegates from over 35 countries are expected to attend, has become the world’s largest and most significant gathering on global private wealth and investment migration, bringing together presidents, prime ministers, senior government ministers and officials, leading academics, private client advisors, family offices, and wealth management professionals, as well as many affluent entrepreneurs and investors.

The 2023 conference program features sophisticated, cutting-edge content on the major developments shaping global wealth planning, investment migration, and geopolitics today.

Notes to Editors

For further information and media accreditation to attend the Henley Global Citizens launch (10 November) and/or the 17th annual Global Citizenship Conference (8-10 November) please contact:

Sarah Nicklin

Group Head of Public Relations

Mobile: +27 72 464 8965

About Henley & Partners

Henley & Partners is the global leader in residence and citizenship by investment. Each year, hundreds of wealthy individuals and their advisors rely on our expertise and experience in this area. The firm’s highly qualified professionals work together as one team in over 40 offices worldwide.

The concept of residence and citizenship by investment was created by Henley & Partners in the 1990s. As globalization has expanded, residence and citizenship have become topics of significant interest among the increasing number of internationally mobile entrepreneurs and investors whom we proudly serve every day.
Henley & Partners also runs the world’s leading government advisory practice for investment migration, which has raised more than USD 12 billion in foreign direct investment. Trusted by governments, the firm has been involved in strategic consulting and in the design, set-up, and operation of the world’s most successful residence and citizenship programs.

About Insignia

Founded in 1996, Insignia began its journey as a provider of travel-related services and payment cards. Today, it has flourished into a comprehensive global luxury consultancy service, offering a bespoke 360-degree approach customized to meet each member’s needs.

With 24/7 access to dedicated personal assistants and an in-house lifestyle team, Insignia brings unprecedented service to its members. Insignia showcases an enviable range of super-premium and premium payment cards, from exquisite jewelry-inspired designs to refined luxury metal finishes. These offer unlimited spending potential and are tailored for business and individual use.

With over 27 years of experience, Insignia has mastered the art of catering to the lifestyle needs of the most influential and affluent individuals across the globe. Membership is by invitation only and is intentionally limited to maintain an atmosphere of exclusivity.

Today it is present in 7 cities – Dubai, London, New York, Hong Kong, Valletta, Bratislava and Geneva.

GlobeNewswire Distribution ID 1000897511

กรณีศึกษาเชิงภาพของ MDC เผยว่าภายในปี 2027 จะมีผู้เล่น VR และ AR สูงถึง 100 ล้านคน

มากกว่าครึ่งหนึ่งของประชากรที่เล่นเกมสนใจเกมยิงมุมมองบุคคลที่หนึ่ง ซึ่งเป็นแนวเกมยอดนิยมในปี 2023

Mapping the Worlds Most Popular Video-Games

Top Video Game Trends and Favourites 2023

ลอนดอน, Nov. 06, 2023 (GLOBE NEWSWIRE) — กรณีศึกษาเชิงภาพครั้งสำคัญที่เผยแพร่โดย MDC (Minimum Deposit Casinos) ได้เผยว่าอุตสาหกรรมเกมทั่วโลกกำลังเฟื่องฟู โดยมีผู้คนนับล้านจากทั่วโลกหันมาให้ความสนใจโลกเสมือนจริงเพื่อเพลิดเพลินกับเกมโปรดตลอดกาลของตนเอง ในปี 2023 มีผู้คนจำนวน 98 ล้านคนที่ใช้เทคโนโลยีเสมือนจริง (VR) และ 23 ล้านคนใช้เทคโนโลยีความเป็นจริงเสริม (AR) โดยคาดว่าในปี 2027 จะมีผู้ใช้ทั้ง AR และ VR เกิน 100 ล้านคนทั่วโลก

MDC พอร์ทัลแหล่งข้อมูล iGaming ร่วมกับ NowSourcing ซึ่งเป็นบริษัทออกแบบที่มีชื่อเสียง ได้ทำการวิจัยและสร้างกรณีศึกษาเชิงภาพที่สมจริง โดยร่างแผนวิดีโอเกมที่ได้รับความนิยมมากที่สุดในสหรัฐอเมริกาและทั่วโลกในปี 2023


  • ประเภทวิดีโอเกมที่ได้รับความนิยมมากที่สุด ได้แก่ เกมยิงมุมมองบุคคลที่หนึ่ง, เกมผจญภัยแอ็กชัน, เกมจำลองสถานการณ์, เกมสมรภูมิการต่อสู้ออนไลน์แบบผู้เล่นหลายคน (MOBA) และเกมกีฬา
  • ความชอบต่อวิดีโอเกมแตกต่างกันไปในแต่ละประเทศ เช่น ฝรั่งเศสชื่นชอบ Pokémon Legends: Arceus ส่วนจีนชอบ Honor of Kings มากกว่า
  • แนวโน้มที่กำลังเกิดขึ้นในอุตสาหกรรมเกมรวมถึงการเล่นเกมด้วยเทคโนโลยี AR และ VR, เกมการออกกำลังกาย และเกมคาสิโน

อุตสาหกรรมเกมได้ก้าวเข้าสู่ยุคทองแล้ว – โดยเทคโนโลยีล้ำสมัยแห่งอนาคตได้จำลองจักรวาลที่ไม่เหมือนใคร เกมเหล่านี้เป็นเกมที่สมจริง ริเริ่มสิ่งใหม่ ๆ และสร้างการมีส่วนร่วมเป็นอย่างมาก ต่างจากเกมที่เคยเห็นมาก่อน แต่เกมประเภทใดที่กำลังมาแรง และเกมประเภทใดที่ได้รับความนิยมมากที่สุดจากผู้เล่น?

อินโฟกราฟิกกรณีศึกษาของ MDC พบว่าเกมยิงมุมมองบุคคลที่หนึ่ง (FPS) เป็นประเภทวิดีโอเกมที่ได้รับความนิยมมากที่สุด ตามมาด้วยเกมผจญภัยแอ็กชัน, เกมจำลองสถานการณ์, เกมสมรภูมิการต่อสู้ออนไลน์แบบผู้เล่นหลายคน (MOBA) และเกมกีฬา คนที่มีอายุระหว่าง 16 ถึง 24 ปีอย่างน้อย 66% มีส่วนร่วมในเกม FPS

นอกจากนี้ เกมวิดีโอที่ได้รับความนิยมมากที่สุดในปี 2023 ก็แตกต่างกันไปในแต่ละประเทศ

ฝรั่งเศสชื่นชอบ Pokémon Legends: Arceus, จีนชอบ Honor of Kings และประเทศอื่น ๆ มีเกมที่ชื่นชอบแบบเฉพาะ เช่น Mario Kart 8 Deluxe (เยอรมนี), Call of Duty: Modern Warfare II (สหราชอาณาจักร), Madden NFL (สหรัฐอเมริกา), Pikmin 4 (ญี่ปุ่น), God of War Ragnarök (รัสเซีย), Remnant II (แคนาดา) และ The Legend of Zelda: Tears of the Kingdom (ออสเตรเลีย)

อุตสาหกรรมเกมยังพัฒนาอย่างต่อเนื่อง โดยมีแนวโน้มใหม่ ๆ เกิดขึ้นอยู่ตลอดเวลา แนวโน้มชั้นนำที่สุดบางส่วน ได้แก่ เกมที่มีเทคโนโลยี AR และ VR, เกมการออกกำลังกาย และเกมคาสิโน

เกม AR และ VR

เกมความเป็นจริงเสริม (AR) และเกมเสมือนจริง (VR) ได้รับการต้อนรับอย่างท่วมท้นในทั่วโลก เกม AR ซ้อนทับข้อมูลดิจิทัลสู่โลกแห่งความเป็นจริง ขณะที่เกม VR จะพาผู้เล่นเข้าสู่โลกเสมือนจริงที่มีความสมจริงอย่างสมบูรณ์

ในปี 2023 มีผู้ใช้ VR จำนวน 98 ล้านคน และผู้ใช้ AR จำนวน 23 ล้านคน โดยคาดว่าในปี 2027 จะมีผู้ใช้ทั้ง AR และ VR เกิน 100 ล้านคนทั่วโลก

เกม AR และ VR บางเกมที่มีผู้เล่นมากที่สุดใน Steam รวมถึง War Thunder, Phasmophobia และ VR Chat

นอกจากนี้ คาดว่าตลาดเกมออกกำลังแบบ VR จะเติบโตขึ้น 40% ระหว่างปี 2023 ถึง 2029


ความบันเทิงในคาสิโนออนไลน์ก็เป็นที่ต้องการในทั่วโลก ในปี 2023 มีธุรกิจเกมออนไลน์ 4,792 แห่งทั่วโลก – โดยเป็นอัตราการเติบโต 29.25% นับตั้งแต่ปี 2018 เกมคาสิโนยอดนิยมบางส่วน ได้แก่ Coin Master, Bingo Blitz และ Jackpot Party Casino Slots

เมื่อมีเกมและแพลตฟอร์มประเภทต่าง ๆ มากมายให้เลือก อุตสาหกรรมเกมทั่วโลกจึงดูมีสีสันกว่าที่เคย

เรียนรู้เพิ่มเติมเกี่ยวกับเกมที่เป็นที่นิยมทั่วโลกได้ที่ MDC:

เกี่ยวกับ MDC

MDC ( เป็นพอร์ทัลแหล่งข้อมูลที่ดีที่สุดของคุณ สำหรับข้อมูลที่ถูกต้องและล่าสุดเกี่ยวกับคาสิโนออนไลน์และเกมที่ดีที่สุดทั่วโลก MDC มุ่งมั่นที่จะให้ข้อมูลเชิงลึกอันมีค่าและส่งเสริมแนวทางปฏิบัติในการเล่นเกมออนไลน์อย่างมีความรับผิดชอบสำหรับผู้ใช้ทั่วโลก ซึ่งนำโดยทีมผู้เชี่ยวชาญด้านคาสิโนออนไลน์




Twitter/X: @MinDeposCasino

GlobeNewswire Distribution ID 1000897725

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis

  • First placebo-controlled randomized trial in active psoriatic arthritis (PsA) using a Nanobody® to report positive topline results in support of potential best-in-class profile
  • Primary endpoint ACR50 met with up to 47% (p<0.01 versus placebo) of patients on sonelokimab achieving ACR50 as early as week 12
  • All key secondary endpoints met including up to 77% (p<0.001 versus placebo) of patients on sonelokimab achieving PASI90 as early as week 12
  • Other secondary endpoints also reached statistical significance at week 12, including endpoints focused on deep tissue inflammation, Minimal Disease Activity (MDA) and patient reported outcomes
  • High threshold outcomes, including ACR70 and PASI100, continue to improve beyond week 12, consistent with previous studies of sonelokimab
  • Discontinuation rate below 4% and safety results of sonelokimab consistent with previously reported studies with no new safety signals
  • The top-line data will be discussed on Monday 6 November, at 2pm CET/8am ET, via webcast (registration link below)

ZUG, Switzerland, November 5, 2023 – MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced positive top-line results from its global Phase 2 ARGO trial evaluating the efficacy and safety of the Nanobody® sonelokimab in patients with active psoriatic arthritis (PsA).

The ARGO trial (M1095-PSA-201), which enrolled 207 patients, met its primary endpoint with a statistically significant greater proportion of patients treated with either sonelokimab 60mg or 120mg (with induction) achieving an American College of Rheumatology (ACR) 50 response compared to those on placebo at
week 12. Specifically, for the 60mg and 120mg doses with induction, respectively, 46% and 47% of patients treated with sonelokimab achieved ACR50 (p<0.01 versus placebo); 78% and 72% of patients achieved ACR20; and 29% and 26% achieved ACR70. The primary analyses were based on the most stringent type of analysis for such trials, intention-to-treat with non-responder imputation (ITT-NRI). As expected, the 60mg dose without induction did not reach statistical significance, confirming the 60mg and 120mg with induction as the potential dose regimens to carry forward into Phase 3.

All key secondary endpoints were met for the 60mg and 120mg doses with induction. The key secondary endpoint Psoriasis Area and Severity Index (PASI) 90 was met for all doses with induction; 77% of patients responding at week 12 to the 60mg dose (ITT-NRI, p<0.001 versus placebo). For this dose, 58% of patients achieved complete skin clearance (PASI100) at week 12. PASI responses across dose arms were consistent with the previously reported Phase 2b data of sonelokimab in moderate-to-severe plaque-type psoriasis, with the 120mg dose achieving the highest responses for PASI100 (close to 60% of patients at week 12, ITT-NRI) in patients with more severe skin lesions (PASI score ≥ 10 at baseline).

Other clinically relevant secondary endpoints, such as Minimal Disease Activity (MDA), the modified Nail Psoriasis Severity Index (mNAPSI), the Leeds Enthesitis Index (LEI) and the patient self-reported Psoriatic Arthritis Impact of Disease (PsAID-12), each show promising levels of response at week 12.

Jorge Santos da Silva, PhD, Founder and Chief Executive Officer at MoonLake, said: “As part of our efforts to elevate outcomes for patients, we set ambitious goals for our Nanobody® sonelokimab. ARGO is MoonLake’s third Phase 2 trial and the first trial in psoriatic arthritis using a Nanobody® to report positive topline results, setting another landmark milestone. Again, we met the objectives we set out for ourselves, in this case for PsA. As with our hidradenitis suppurativa program, the preparation of our Phase 3 program in PsA is rapidly advancing and expected timing of end-of-Phase 2 regulatory meetings will be announced in due course.”

Adalimumab was used as an active reference to validate responses across arms (not powered for statistical comparisons to active treatment). Sonelokimab 60mg and 120mg (with induction) numerically outperformed adalimumab on the primary endpoint and all key secondary endpoints, with the observed deltas further supporting the potential for sonelokimab as a future leading therapy.

The patient discontinuation rate in the ARGO trial was low at week 12 (less than 4%), similar to what was observed in previous trials of sonelokimab in psoriasis and hidradenitis suppurativa. The safety profile of sonelokimab in ARGO was consistent with previously reported studies with no new safety signals. Specifically, oral candidiasis was observed in less than 2% of patients on sonelokimab, with no case leading to discontinuation. No cases of inflammatory bowel disease (IBD), major adverse cardiovascular events (MACE) or suicidal ideation and behavior (SI/B) were observed. Overall, sonelokimab continues to show a favorable safety profile. Across the sonelokimab clinical program to date, the company has not seen any signal of SI/B or liver enzyme elevations related to sonelokimab treatment.

The results suggest that, as early as week 12, the Nanobody® sonelokimab reaches levels of clinical response at or above those seen with other therapies tested in similarly stringent trials. The high performance of sonelokimab and its favorable safety profile continue to support the potential of using a smaller biologic with albumin-binding capacity to inhibit IL-17A and IL-17F for the treatment of inflammatory diseases.

Kristian Reich, MD, PhD, Founder and Chief Scientific Officer at MoonLake, commented: The positive topline results from the pivotal-like ARGO trial establish the Nanobody® sonelokimab as an innovative potential treatment in another chronic inflammatory disease, psoriatic arthritis. Importantly, the results confirm our expectations in terms of dosing, clinical responses and safety findings. We believe that we have elevated the therapeutic bar by reaching important clinical outcomes at week 12. The data also support sonelokimab’s unique molecule characteristics and mode of action to effectively inhibit IL-17F in addition to IL-17A in deep tissue inflammation. The positive outcome of the ARGO trial would not have been possible without the support and participation of the patients and investigators to whom we are grateful.”

Joseph F. Merola, MD, MMSc, Professor of Dermatology, Medicine and Rheumatology, Distinguished Chair of Dermatology at UT Southwestern Medical Center added: “Psoriatic arthritis is a chronic, inflammatory, recurrent, and debilitating multidomain disease that has profound and wide-ranging impacts across many aspects of patients’ lives. As a physician, I see tremendous need for new treatment options for people living with PsA, particularly for therapies that reach high thresholds of response (e.g., ACR70, PASI100) and that simultaneously improve the disease domains that matter most for patients. The positive high clinical responses across joint and skin endpoints and stringent composite measures such as minimal disease activity observed with sonelokimab as early as week 12 in the Phase 2 ARGO trial are encouraging, demonstrating its promise as a potential future treatment option.”

These topline data will be discussed on Monday November 6, 2023 at 2pm CET/8am ET before the Nasdaq market opens, via webcast at:

A replay of the webcast and the presentation document will be made available at

The ARGO trial proceeds to week 24, with a 4-week safety follow-up. Important data is being collected regarding longer-term efficacy and safety of sonelokimab, as well as results from the cross-over of patients treated with placebo or adalimumab to sonelokimab and the continued monthly dosing of sonelokimab.

Today’s top-line data announcement follows the announcement in July 2023 that the ARGO trial successfully completed randomization of its target 200 patients, several weeks ahead of schedule (read more here). Full results from the ARGO trial will be submitted for publication in a peer-reviewed medical journal and for presentation at an upcoming scientific meeting.

The positive top-line12-week results from the Phase 2 ARGO trial in PsA follows the positive top-line 12-week and 24-week results from the Phase 2 MIRA trial in hidradenitis suppurativa (HS) as announced in June 2023 (read more here) and October 2023 (read more here). The MIRA trial set a landmark milestone as the first placebo-controlled randomized trial in HS to report positive top-line results using HiSCR75 as the primary endpoint.

Sonelokimab is not yet approved for use in any indication.

About Psoriatic Arthritis

Psoriatic arthritis (PsA) is a chronic and progressive inflammatory arthritis associated with psoriasis primarily affecting the peripheral joints. The clinical features of PsA are diverse, involving pain, swelling, and stiffness of the joints, which can result in restricted mobility and fatigue. PsA occurs in up to 30% of patients with psoriasis, most commonly those aged between 30 and 60 years. The symptom burden of PsA can have a substantial negative impact on patient quality of life. Although the exact mechanism of disease is not fully understood, evidence suggests that activation of the IL-17 pathway plays an important role in the disease pathophysiology.

About the ARGO trial

The ARGO trial (M1095-PSA-201) is a global, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of the Nanobody® sonelokimab, administered subcutaneously, in the treatment of adult patients with active PsA. The trial is designed to evaluate different doses of sonelokimab, with placebo control and adalimumab as an active reference arm. The primary endpoint of the trial is the percentage of participants achieving ≥50% improvement in signs and symptoms of disease from baseline, compared to placebo, as measured by the American College of Rheumatology (ACR) 50 response. The trial also evaluates a number of secondary endpoints, including improvement compared to placebo in ACR20, complete skin clearance as measured by at least a 100% improvement in the Psoriasis Area and Severity Index (PASI), physical function as measured by the Health Assessment Questionnaire-Disability Index, enthesitis as measured by the Leeds Enthesitis Index and pain as measured by the Patients Assessment of Arthritis Pain. Further details are available on:

About Sonelokimab

Sonelokimab (M1095) is an investigational ~40 kDa humanized Nanobody® consisting of three VHH domains covalently linked by flexible glycine-serine spacers. With two domains, sonelokimab selectively binds with high affinity to IL-17A and IL-17F, thereby inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers. A third central domain binds to human albumin, facilitating further enrichment of sonelokimab at sites of inflammatory edema.

Sonelokimab is being assessed in two trials, the Phase 2 ARGO trial in PsA (trial ongoing) and the Phase 2 MIRA trial in HS. In June 2023, topline results of the MIRA trial (NCT05322473) at 12 weeks showed that the trial met its primary endpoint, the Hidradenitis Suppurativa Clinical Response (HiSCR)75, which is a higher measure of clinical response versus the HiSCR50 measure used in other clinical trials, setting a landmark milestone. In October 2023, the full dataset from the MIRA trial at 24 weeks showed that maintenance treatment with sonelokimab led to further improvements in HiSCR75 response rates and other clinically relevant outcomes.

Sonelokimab has also been assessed in a randomized, placebo-controlled Phase 2b trial (NCT03384745) in 313 patients with moderate-to-severe plaque-type psoriasis. Clinical response (considering the Investigator’s Global Assessment Score 0 or 1, and the Psoriasis Area and Severity Index 90/100) was observed in patients with moderate-to-severe plaque-type psoriasis. Sonelokimab was generally well tolerated, with a safety profile similar to the active control, secukinumab (Papp KA, et al. Lancet. 2021; 397:1564-1575).

In an earlier Phase 1 trial in patients with moderate-to-severe plaque-type psoriasis, sonelokimab has been shown to decrease (to normal skin levels) the cutaneous gene expression of pro-inflammatory cytokines and chemokines (Svecova D. J Am Acad Dermatol. 2019;81:196–203).

About Nanobodies®

Nanobodies® represent a new generation of antibody-derived targeted therapies. They consist of one or more domains based on the small antigen-binding variable regions of heavy-chain-only antibodies (VHH). Nanobodies® have a number of potential advantages over traditional antibodies, including their small size, enhanced tissue penetration, resistance to temperature changes, ease of manufacturing, and their ability to be designed into multivalent therapeutic molecules with bespoke target combinations.

The terms Nanobody® and Nanobodies® are trademarks of Ablynx, a Sanofi company.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, a novel investigational Nanobody® for the treatment of inflammatory disease, to revolutionize outcomes for patients. Sonelokimab inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation. The company’s focus is on inflammatory diseases with a major unmet need, including hidradenitis suppurativa and psoriatic arthritis – conditions affecting millions of people worldwide with a large need for improved treatment options. MoonLake was founded in 2021 and is headquartered in Zug, Switzerland. Further information is available at The terms Nanobody® and Nanobodies® are trademarks of Ablynx, a Sanofi company.

Cautionary Statement Regarding Forward Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding MoonLake’s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: plans for clinical trials and research and development programs; and the anticipated timing of the results from those trials, including completing the MIRA trial and top-line data from the ARGO trial; and the efficacy of our products, if approved, including in relation to other products. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking.

Forward-looking statements are based on current expectations and assumptions that, while considered reasonable by MoonLake and its management, as the case may be, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with MoonLake’s business in general and limited operating history, difficulty enrolling patients in clinical trials, and reliance on third parties to conduct and support its clinical trials, and the other risks described in or incorporated by reference into MoonLake’s Annual Report on Form 10-K for the year ended December 31, 2022 and subsequent filings with the Securities and Exchange Commission.

Nothing in this press release should be regarded as a representation by any person that the forward- looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. MoonLake does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or in the events, conditions or circumstances on which any such statement is based.

MoonLake Immunotherapeutics Investors
Matthias Bodenstedt, CFO

MoonLake Immunotherapeutics Media
Patricia Sousa

ICR Consilium
Mary-Jane Elliott, Namrata Taak, Ashley Tapp
Tel: +44 (0) 20 3709 5700

GlobeNewswire Distribution ID 1000897698

Cuba expressed solidarity with Nepal after suffering earthquake

The Minister of Foreign Affairs of Cuba, Bruno Rodríguez, today expressed his country’s solidarity with the people and Government of Nepal, for the loss of human life caused by an earthquake in that Asian nation, from his account on the X social network.

Nepalese authorities reported that at least 157 people died and another hundred were injured by a nighttime earthquake, which also shook hard northern India.

The 5.6 magnitude earthquake had its epicenter in the western end of the Asian nation, 42 kilometers south of Jumla in Karnali province, and 18 kilometers deep, according to the United States Geological Survey.

Nepal is located on a major geological fault line, where the Indian tectonic plate pushes towards the Eurasian plate, forming the Himalayas, while telluric events occur regularly.

Source: Lao News Agency